Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimustine + tegafur
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intracarotid Infusion, Oral
01
Overview
A combination of nimustine (ACNU) and tegafur used in cancer treatment, particularly for malignant gliomas. This combination is part of AUFRAP therapy, which includes ACNU (nimustine), UFT (tegafur + uracil), Radiation, vitamin A, and PSK (krestin). Nimustine is an alkylating agent administered via intracarotid infusion, while tegafur is an antineoplastic agent that functions as a prodrug of 5-fluorouracil (5-FU).
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on nimustine + tegafur.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimustine + tegafur.